257 related articles for article (PubMed ID: 34211840)
41. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
Butrynski JE; D'Adamo DR; Hornick JL; Dal Cin P; Antonescu CR; Jhanwar SC; Ladanyi M; Capelletti M; Rodig SJ; Ramaiya N; Kwak EL; Clark JW; Wilner KD; Christensen JG; Jänne PA; Maki RG; Demetri GD; Shapiro GI
N Engl J Med; 2010 Oct; 363(18):1727-33. PubMed ID: 20979472
[TBL] [Abstract][Full Text] [Related]
42. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
43. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.
Gambacorti-Passerini C; Orlov S; Zhang L; Braiteh F; Huang H; Esaki T; Horibe K; Ahn JS; Beck JT; Edenfield WJ; Shi Y; Taylor M; Tamura K; Van Tine BA; Wu SJ; Paolini J; Selaru P; Kim TM
Am J Hematol; 2018 May; 93(5):607-614. PubMed ID: 29352732
[TBL] [Abstract][Full Text] [Related]
44. Uterine mesenchymal tumors harboring
Kyi C; Friedman CF; Mueller JJ; Benayed R; Ladanyi M; Arcila M; Yang SR; Hensley ML; Chiang S
Gynecol Oncol Rep; 2021 Aug; 37():100852. PubMed ID: 34522753
[TBL] [Abstract][Full Text] [Related]
45. Podcast on Emerging Treatment Options for Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumors.
Lowe E; Mossé YP
Oncol Ther; 2024 Jun; 12(2):247-255. PubMed ID: 38676786
[TBL] [Abstract][Full Text] [Related]
46. Inflammatory myofibroblastic tumor and low-grade myofibroblastic sarcoma: a comparative study of clinicopathologic features and further observations on the immunohistochemical profile of myofibroblasts.
Qiu X; Montgomery E; Sun B
Hum Pathol; 2008 Jun; 39(6):846-56. PubMed ID: 18400254
[TBL] [Abstract][Full Text] [Related]
47. Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
Zhang Y; Zhang X; Zhang R; Xu Q; Yang H; Lizaso A; Xu C; Liu J; Wang W; Ou SI; Zhang J; Song Z; Yang N
BMC Med; 2021 Sep; 19(1):206. PubMed ID: 34511132
[TBL] [Abstract][Full Text] [Related]
48. Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring
Zhao T; Zhang X; Liu X; Ren M; Cheng Y; Wang J; Luo Z
Front Oncol; 2023; 13():1147974. PubMed ID: 37035208
[TBL] [Abstract][Full Text] [Related]
49.
Michels SYF; Scheel AH; Wündisch T; Heuckmann JM; Menon R; Puesken M; Kobe C; Pasternack H; Heydt C; Scheffler M; Fischer R; Schultheis AM; Merkelbach-Bruse S; Heukamp L; Büttner R; Wolf J
NPJ Precis Oncol; 2017; 1(1):4. PubMed ID: 29872693
[TBL] [Abstract][Full Text] [Related]
50. A unique case of inflammatory myofibroblastic tumor of the liver manifesting with biloma: A case report.
Huang K; Zhao P; Zhao J; Zhao P; Yang J
Oncol Lett; 2022 Jul; 24(1):227. PubMed ID: 35720485
[TBL] [Abstract][Full Text] [Related]
51. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
52. Inflammatory myofibroblastic tumor of bone harboring an ALK gene amplification.
Wang K; Guo R; Siegal GP; Wei S
Pathol Res Pract; 2019 Sep; 215(9):152535. PubMed ID: 31326196
[TBL] [Abstract][Full Text] [Related]
53. Inflammatory Myofibroblastic Tumor With
Schoot RA; Orbach D; Minard Colin V; Alaggio R; Di Carlo D; Corradini N; Mercolini F; Milano GM; van Noesel MM; Rome A; Dall'Igna P; Pajtler K; Sparber-Sauer M; Ferrari A; Casanova M
JCO Precis Oncol; 2023 Sep; 7():e2300323. PubMed ID: 37856763
[TBL] [Abstract][Full Text] [Related]
54. ROS1 rearrangements define a unique molecular class of lung cancers.
Bergethon K; Shaw AT; Ou SH; Katayama R; Lovly CM; McDonald NT; Massion PP; Siwak-Tapp C; Gonzalez A; Fang R; Mark EJ; Batten JM; Chen H; Wilner KD; Kwak EL; Clark JW; Carbone DP; Ji H; Engelman JA; Mino-Kenudson M; Pao W; Iafrate AJ
J Clin Oncol; 2012 Mar; 30(8):863-70. PubMed ID: 22215748
[TBL] [Abstract][Full Text] [Related]
55. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
56. Inflammatory myofibroblastic tumor of the submandibular gland Harboring MSN-ALK gene fusion: A case report and literature review.
Diao L; Li W; Jiang Q; Huang H; Zhou E; Peng B; Chen X; Zeng Z; He C
Heliyon; 2023 Dec; 9(12):e22928. PubMed ID: 38144359
[TBL] [Abstract][Full Text] [Related]
57. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
[TBL] [Abstract][Full Text] [Related]
58. STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.
Subbiah V; McMahon C; Patel S; Zinner R; Silva EG; Elvin JA; Subbiah IM; Ohaji C; Ganeshan DM; Anand D; Levenback CF; Berry J; Brennan T; Chmielecki J; Chalmers ZR; Mayfield J; Miller VA; Stephens PJ; Ross JS; Ali SM
J Hematol Oncol; 2015 Jun; 8():66. PubMed ID: 26062823
[TBL] [Abstract][Full Text] [Related]
59. Gene fusion involving the insulin-like growth factor 1 receptor in an ALK-negative inflammatory myofibroblastic tumour.
Piarulli G; Puls F; Wängberg B; Fagman H; Hansson M; Nilsson J; Arbajian E; Mertens F
Histopathology; 2019 Jun; 74(7):1098-1102. PubMed ID: 30735274
[TBL] [Abstract][Full Text] [Related]
60. Anaplastic Lymphoma Kinase Positive Mesenteric Inflammatory Myofibroblastic Tumor in Adult Woman.
Lee CS; Kim JS; Rodriguez R; Krell RW
Cureus; 2022 Apr; 14(4):e24422. PubMed ID: 35637807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
